Chemotherapy, with Fluoropyrimidine, Oxaliplatin, or Irinotecan given sequentially or in combination, is considered the backbone of management for metastatic colorectal cancer (mCRC), even if monoclonal antibodies targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptors (EGFR) in RAS wild-type tumours provided an additional mechanism for disease control in this cohort of patients [4]. The gene discussed is VEGFA; the disease is neoplasm.